Compare MCHX & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCHX | EDAP |
|---|---|---|
| Founded | 2003 | 1979 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 75.5M |
| IPO Year | 2004 | 1997 |
| Metric | MCHX | EDAP |
|---|---|---|
| Price | $1.70 | $3.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 22.2K | ★ 77.3K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $46,494,000.00 | ★ $74,853,925.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.70 | $2.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 0.61 |
| 52 Week Low | $1.26 | $1.21 |
| 52 Week High | $2.31 | $3.92 |
| Indicator | MCHX | EDAP |
|---|---|---|
| Relative Strength Index (RSI) | 55.25 | 71.31 |
| Support Level | $1.59 | $3.15 |
| Resistance Level | $1.69 | $3.45 |
| Average True Range (ATR) | 0.07 | 0.32 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 68.79 | 82.39 |
Marchex Inc harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales, and marketing teams to optimize customer journey experiences across communications channels, enabling enterprise strategies, empowering businesses to increase revenue through informed decision-making and strategic execution.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.